Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Extension Study To Evaluate The Long-Term Safety And Efficacy Of Fenebrutinib In Patients Previously Enrolled In A Fenebrutinib Chronic Spontaneous Urticaria Study

NCT03693625 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT03693625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03693625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Extension Study To Evaluate The Long-Term Safety And Efficacy Of Fenebrutinib In Patients Previously Enrolled In A Fenebrutinib Chronic Spontaneous Urticaria Study
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
September 27, 2018
Completion date
October 23, 2019
Enrollment
31 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

urticaria